Arvinas Operations Inc. has synthesized proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.
Scorpion Therapeutics Inc. has found compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.
Researchers from Vividion Therapeutics Inc. and partner Roche Holdings AG have published the discovery and preclinical characterization of the novel covalent allosteric inhibitor of WRN, VVD-133214 (RO-7589831).
Fogpharma Inc. and Artbio Inc. have established a collaboration to co-develop a new class of α-radioligand therapeutics to maximize efficacy for patients with multiple types of cancer.
Pheast Therapeutics Inc. has announced the presentation of preclinical data for PHST-001, a therapeutic monoclonal antibody targeting CD24, a macrophage checkpoint.
At last week’s ASGCT meeting, Adicet Bio Inc. presented a new CAR T-cell therapy, ADI-270, for the treatment of CD70-expressing tumors. ADI-270 uses CD27 as the binding domain and 4-1BB co-stimulatory domains plus CD3.
As South Korea’s Curocell Inc. looks to develop the country’s first homegrown CAR T-cell therapy, CEO Gunsoo Kim highlighted rising and falling trends in the global CAR T development space at Bio Korea 2024.
Citing a high rate of patients leaving the study, Merck & Co. Inc. has discontinued the anti-TIGIT antibody vibostolimab and the anti-PD-1 Keytruda (pembrolizumab) portion of it phase III Keyvibe-10 trial as an adjuvant treatment for those with resected high-risk melanoma.